Ronco Claudio, Kellum John A, Mehta Ravindra
Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy.
Adv Ren Replace Ther. 2002 Oct;9(4):248-51. doi: 10.1053/jarr.2002.35565.
Over 300,000 Americans develop acute renal failure each year, and half die. In recent years, there have been considerable advances in our understanding and technical capabilities, but consensus over the optimal way to deliver care does not exist. Consequently, a conference held in New York in the year 2000 has given birth to the Acute Dialysis Quality Initiative (ADQI). The conference aimed at establishing an evidence-based appraisal and set of consensus recommendations to standardize care and direct further research on the application of continuous renal replacement therapy (CRRT). CRRT is being used at ever-increasing rates in the United States. Today, approximately one quarter of all patients with acute renal failure are treated with CRRT. Despite the increasing use, there are presently no published standards for the application of this therapy, and practice patterns vary widely between individual centers. Results from recent clinical trials on selection of dialysis membranes and dialysis dose provide strong, yet often conflicting, evidence to guide therapy. Other areas of uncertainty have not been sufficiently addressed by clinical studies and directives for future research are needed. Finally, the success of multicentered clinical trials in supportive care in the intensive care unit (transfusion thresholds and ventilator management) have intensified and renewed interest in the study of supportive care methods as a major target for future research. These developments have set the stage for the first ADQI conference; the final objectives are the development of evidence-based practice guidelines and directions for future research.
每年有超过30万美国人发生急性肾衰竭,其中半数死亡。近年来,我们在认识和技术能力方面取得了长足进展,但对于提供最佳治疗的方式尚未达成共识。因此,2000年在纽约召开的一次会议催生了急性透析质量倡议(ADQI)。该会议旨在建立基于证据的评估及一系列共识性建议,以规范治疗并指导关于持续肾脏替代治疗(CRRT)应用的进一步研究。在美国,CRRT的使用频率正在不断增加。如今,所有急性肾衰竭患者中约有四分之一接受CRRT治疗。尽管其使用越来越多,但目前尚无该治疗应用的公开标准,各个中心的实践模式差异很大。近期关于透析膜选择和透析剂量的临床试验结果提供了有力但往往相互矛盾的证据来指导治疗。临床研究尚未充分解决其他一些不确定领域,因此需要针对未来研究发布指令。最后,重症监护病房支持治疗的多中心临床试验(输血阈值和呼吸机管理)取得成功,这使得人们对支持治疗方法的研究兴趣大增,并将其作为未来研究的主要目标重新提起。这些进展为首次ADQI会议奠定了基础;最终目标是制定基于证据的实践指南以及未来研究方向。